Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Continuous levosimendan infusion for refractory cardiogenic shock complicating severe acute dichlorvos poisoning.

Liu Y, Liu B, Zhou H, Wei LQ.

Am J Med Sci. 2012 Aug;344(2):166-70. doi: 10.1097/MAJ.0b013e318254490d.

PMID:
22771967
2.

Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines.

Delle Karth G, Buberl A, Geppert A, Neunteufl T, Huelsmann M, Kopp C, Nikfardjam M, Berger R, Heinz G.

Acta Anaesthesiol Scand. 2003 Nov;47(10):1251-6.

PMID:
14616323
3.

[Therapy of acute decompensated heart failure with levosimendan].

Müller K, Peters A, Zeus T, Hennersdorf M, Strauer BE.

Med Klin (Munich). 2006 Mar 22;101 Suppl 1:119-22. German.

PMID:
16802535
4.

Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction.

Fuhrmann JT, Schmeisser A, Schulze MR, Wunderlich C, Schoen SP, Rauwolf T, Weinbrenner C, Strasser RH.

Crit Care Med. 2008 Aug;36(8):2257-66. doi: 10.1097/CCM.0b013e3181809846. Erratum in: Crit Care Med. 2008 Oct;36(10):2966.

PMID:
18664782
5.

Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock.

Russ MA, Prondzinsky R, Christoph A, Schlitt A, Buerke U, Söffker G, Lemm H, Swyter M, Wegener N, Winkler M, Carter JM, Reith S, Werdan K, Buerke M.

Crit Care Med. 2007 Dec;35(12):2732-9.

PMID:
17893627
6.

Cardiogenic shock after primary percutaneous coronary intervention: Effects of levosimendan compared with dobutamine on haemodynamics.

García-González MJ, Domínguez-Rodríguez A, Ferrer-Hita JJ, Abreu-González P, Muñoz MB.

Eur J Heart Fail. 2006 Nov;8(7):723-8. Epub 2006 Feb 21.

7.

Right ventricular function in myocardial infarction complicated by cardiogenic shock: Improvement with levosimendan.

Russ MA, Prondzinsky R, Carter JM, Schlitt A, Ebelt H, Schmidt H, Lemm H, Heinroth K, Soeffker G, Winkler M, Werdan K, Buerke M.

Crit Care Med. 2009 Dec;37(12):3017-23. doi: 10.1097/CCM.0b013e3181b0314a.

PMID:
19661807
8.

[Successful use of levosimendan in a patient with cardiogenic shock complicating acute myocardial infarction].

Mustapha F, Moufida H, Nedia B, Anis L, Iheb L, Habib H.

Tunis Med. 2005 Oct;83(10):635-7. French.

PMID:
16370217
9.

Effects of levosimendan versus dobutamine on left ventricular diastolic function in patients with cardiogenic shock after primary angioplasty.

Dominguez-Rodriguez A, Samimi-Fard S, Garcia-Gonzalez MJ, Abreu-Gonzalez P.

Int J Cardiol. 2008 Aug 18;128(2):214-7. Epub 2007 Jul 23.

PMID:
17643535
10.

Levosimendan as rescue therapy in severe cardiogenic shock after ST-elevation myocardial infarction.

Greif M, Zwermann L, Reithmann C, Weis M.

Acute Card Care. 2008;10(3):185-90. doi: 10.1080/17482940801935774.

PMID:
18972629
11.

Hemodynamic effects of levosimendan in acute myocardial infarction complicated by cardiogenic shock and high systemic vascular resistance.

Tsagalou EP, Kanakakis J, Anastasiou-Nana MI, Drakos SG, Ntalianis AS, Malliaras K, Lazaris N, Katsaros F, Nanas JN.

Acute Card Care. 2009;11(2):99-106. doi: 10.1080/17482940902807286.

PMID:
19353405
12.

The effects of Levosimendan on global haemodynamics in patients with cardiogenic shock.

Rokyta R Jr, Pechman V.

Neuro Endocrinol Lett. 2006 Feb-Apr;27(1-2):121-7.

PMID:
16648778
13.

Levosimendan in patients with cardiogenic shock undergoing surgical revascularization: a case series.

Lehmann A, Lang J, Boldt J, Isgro F, Kiessling AH.

Med Sci Monit. 2004 Aug;10(8):MT89-93. Epub 2004 Jul 23.

PMID:
15278007
14.

Levosimendan in the treatment of cardiogenic shock.

Buerkem B, Lemm H, Krohe K, Dietz S, Raaz U, Buerke U, Russ M, Schlitt A, Werdan K.

Minerva Cardioangiol. 2010 Aug;58(4):519-30.

PMID:
20938415
15.
16.

Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators.

Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, Hutchins S, Leier CV, LeJemtel TH, Loh E, Nicklas J, Ogilby D, Singh BN, Smith W.

Circulation. 2000 Oct 31;102(18):2222-7.

17.

Early and sustained haemodynamic improvement with levosimendan compared to intraaortic balloon counterpulsation (IABP) in cardiogenic shock complicating acute myocardial infarction.

Christoph A, Prondzinsky R, Russ M, Janusch M, Schlitt A, Lemm H, Reith S, Werdan K, Buerke M.

Acute Card Care. 2008;10(1):49-57.

PMID:
17924229
18.

Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.

Follath F.

Ital Heart J. 2003 May;4 Suppl 2:34S-38S.

PMID:
14635368
19.

Levosimendan produces an additional clinical and hemodynamic benefit in patients with decompensated heart failure successfully submitted to a fluid removal treatment.

Giglioli C, Cecchi E, Landi D, Chiostri M, Spini V, Valente S, Gensini GF, Romano SM.

Congest Heart Fail. 2012 Jan-Feb;18(1):47-53. doi: 10.1111/j.1751-7133.2011.00261.x. Epub 2011 Nov 12.

20.

Prophylactic preoperative levosimendan administration in heart failure patients undergoing elective non-cardiac surgery: a preliminary report.

Katsaragakis S, Kapralou A, Drimousis P, Markogiannakis H, Larentzakis A, Kofinas G, Misthos P, Filis K, Theodorou D.

Hellenic J Cardiol. 2009 May-Jun;50(3):185-92.

Items per page

Supplemental Content

Write to the Help Desk